Epilepsy & Seizures

Filter Your Results




Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

Thursday, May 17, 2018—Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed…

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

Wednesday, May 16, 2018—UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures. &n…

Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures

Tuesday, May 01, 2018—The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce…

Obstructive Sleep Apnea and Epilepsy

Michelle L. Dougherty, MD; and Karin G. Johnson, MD

May 2018—It is important to consider comorbid sleep disorders for patients with epilepsy.

Perampanel Safety, Efficacy, and Predictors of Major Response

Friday, April 27, 2018—Perampanel (FYCOMPA; Eisai, Woodcliff Lake, NJ) is approved for use as monotherapy for treatment of partial-onset seizures (POS) with or without secondarily generalized seizur…

Advisory Committee Supports Approval of Oral Cannabidiol for Dravet Syndrome and Lennox-Gastaut Syndrome

Thursday, April 19, 2018—The Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) unanimously recommended supporting the approval of the investigati…

Everolimus Approved as Adjunctive Treatment for Tuberous Sclerosis-Associated Partial-Onset Seizures

Wednesday, April 11, 2018—The Food and Drug Administration (FDA) has granted approval for the use of everolimus (Afinitor DISPERZ; Novartis, East Hanover, NJ) to treat tuberous sclerosis complex (TSC)-…

Approval Sought for use of Perampanel in Pediatric Patients With Epilepsy

Friday, March 30, 2018—A supplemental new drug application (sNDA) has been submitted seeking priority review for the use of perampanel (CIII) (FYCOMPA; Eisai Inc, Woodcliff Lake, NJ) for specif…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.